• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Viela Bio, Inc.

    3/17/21 7:40:24 AM ET
    $VIE
    Major Pharmaceuticals
    Health Care
    Get the next $VIE alert in real time by email
    SC 13D/A 1 a21-10036_1sc13da.htm SC 13D/A

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13D

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 3)

     

    Viela Bio, Inc.

    (Name of Issuer)

     

    Common Stock, Par Value $0.001

    (Title of Class of Securities)

     

    926613100

    (CUSIP Number)

     

    Geraine Chan

    Boundless Meadow Limited

    Suite 1518, Two Pacific Place,

    88 Queensway, Hong Kong

    People’s Republic of China

    +852 3987 1788

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

     

    March 15, 2021

    (Date of Event which Requires Filing of this Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 1(f) or 1(g), check the following box. o

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section of the Exchange Act but shall be subject to all other provisions of the Exchange Act (however, see the Notes).

     


     

    SCHEDULE 13D

     

    CUSIP No. 926613100

     

     

     

    1.

     

    Names of Reporting Persons.

    Boundless Meadow Limited

    2.

     

    Check the Appropriate Box if a Member of a Group (See Instructions).

    (a) o (b) o

    3.

     

    SEC Use Only

    4.

     

    Source of Funds (See Instructions)

    WC

    5.

     

    Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) o

    6.

     

    Citizenship or Place of Organization

    Cayman Islands

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With

     

    7.

     

    Sole Voting Power

    0

     

    8.

     

    Shared Voting Power

    0

     

    9.

     

    Sole Dispositive Power

    0

     

    10.

     

    Shared Dispositive Power

    0

    11.

     

    Aggregate Amount Beneficially Owned by Each Reporting Person

    0

    12.

     

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

    o

    13.

     

    Percent of Class Represented by Amount in Row (11)

    0%

    14.

     

    Type of Reporting Person (See Instructions)

    CO

     

    2


     

    CUSIP No. 926613100

     

     

     

    1.

     

    Names of Reporting Persons.

    Boyu Capital Fund III, L.P.

    2.

     

    Check the Appropriate Box if a Member of a Group (See Instructions).

    (a) o (b) o

    3.

     

    SEC Use Only

    4.

     

    Source of Funds (See Instructions)

    WC

    5.

     

    Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) o

    6.

     

    Citizenship or Place of Organization

    Cayman Islands

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With

     

    7.

     

    Sole Voting Power

    0

     

    8.

     

    Shared Voting Power

    0

     

    9.

     

    Sole Dispositive Power

    0

     

    10.

     

    Shared Dispositive Power

    0

    11.

     

    Aggregate Amount Beneficially Owned by Each Reporting Person

    0

    12.

     

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

    o

    13.

     

    Percent of Class Represented by Amount in Row (11)

    0%

    14.

     

    Type of Reporting Person (See Instructions)

    PN

     

    3


     

    CUSIP No. 926613100

     

     

     

    1.

     

    Names of Reporting Persons.

    Boyu Capital General Partner III, L.P.

    2.

     

    Check the Appropriate Box if a Member of a Group (See Instructions).

    (a) o (b) o

    3.

     

    SEC Use Only

    4.

     

    Source of Funds (See Instructions)

    N/A

    5.

     

    Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) o

    6.

     

    Citizenship or Place of Organization

    Cayman Islands

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With

     

    7.

     

    Sole Voting Power

    0

     

    8.

     

    Shared Voting Power

    0

     

    9.

     

    Sole Dispositive Power

    0

     

    10.

     

    Shared Dispositive Power

    0

    11.

     

    Aggregate Amount Beneficially Owned by Each Reporting Person

    0

    12.

     

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

    o

    13.

     

    Percent of Class Represented by Amount in Row (11)

    0%

    14.

     

    Type of Reporting Person (See Instructions)

    PN

     

    4


     

    CUSIP No. 926613100

     

     

     

    1.

     

    Names of Reporting Persons.

    Boyu Capital General Partner III, Ltd.

    2.

     

    Check the Appropriate Box if a Member of a Group (See Instructions).

    (a) o (b) o

    3.

     

    SEC Use Only

    4.

     

    Source of Funds (See Instructions)

    N/A

    5.

     

    Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) o

    6.

     

    Citizenship or Place of Organization

    Cayman Islands

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With

     

    7.

     

    Sole Voting Power

    0

     

    8.

     

    Shared Voting Power

    0

     

    9.

     

    Sole Dispositive Power

    0

     

    10.

     

    Shared Dispositive Power

    0

    11.

     

    Aggregate Amount Beneficially Owned by Each Reporting Person

    0

    12.

     

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

    o

    13.

     

    Percent of Class Represented by Amount in Row (11)

    0%

    14.

     

    Type of Reporting Person (See Instructions)

    CO

     

    5


     

    CUSIP No. 926613100

     

     

     

    1.

     

    Names of Reporting Persons.

    Boyu Capital Opportunities Master Fund

    2.

     

    Check the Appropriate Box if a Member of a Group (See Instructions).

    (a) o (b) o

    3.

     

    SEC Use Only

    4.

     

    Source of Funds (See Instructions)

    WC

    5.

     

    Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

    o

    6.

     

    Citizenship or Place of Organization

    Cayman Islands

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With

     

    7.

     

    Sole Voting Power

    0

     

    8.

     

    Shared Voting Power

    0

     

    9.

     

    Sole Dispositive Power

    0

     

    10.

     

    Shared Dispositive Power

    0

    11.

     

    Aggregate Amount Beneficially Owned by Each Reporting Person

    0

    12.

     

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

    o

    13.

     

    Percent of Class Represented by Amount in Row (11)

    0%

    14.

     

    Type of Reporting Person (See Instructions)

    CO

     

    6


     

    CUSIP No. 926613100

     

     

     

    1.

     

    Names of Reporting Persons.

    Boyu Capital Investment Management Ltd.

    2.

     

    Check the Appropriate Box if a Member of a Group (See Instructions).

    (a) o (b) o

    3.

     

    SEC Use Only

    4.

     

    Source of Funds (See Instructions)

    N/A

    5.

     

    Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

    o

    6.

     

    Citizenship or Place of Organization

    Cayman Islands

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With

     

    7.

     

    Sole Voting Power

    0

     

    8.

     

    Shared Voting Power

    0

     

    9.

     

    Sole Dispositive Power

    0

     

    10.

     

    Shared Dispositive Power

    0

    11.

     

    Aggregate Amount Beneficially Owned by Each Reporting Person

    0

    12.

     

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

    o

    13.

     

    Percent of Class Represented by Amount in Row (11)

    0%

    14.

     

    Type of Reporting Person (See Instructions)

    CO

     

    7


     

    CUSIP No. 926613100

     

     

     

    1.

     

    Names of Reporting Persons.

    Boyu Capital Group Holdings Ltd.

    2.

     

    Check the Appropriate Box if a Member of a Group (See Instructions).

    (a) o (b) o

    3.

     

    SEC Use Only

    4.

     

    Source of Funds (See Instructions)

    N/A

    5.

     

    Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

    o

    6.

     

    Citizenship or Place of Organization

    Cayman Islands

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With

     

    7.

     

    Sole Voting Power

    0

     

    8.

     

    Shared Voting Power

    0

     

    9.

     

    Sole Dispositive Power

    0

     

    10.

     

    Shared Dispositive Power

    0

    11.

     

    Aggregate Amount Beneficially Owned by Each Reporting Person

    0

    12.

     

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

    o

    13.

     

    Percent of Class Represented by Amount in Row (11)

    0%

    14.

     

    Type of Reporting Person (See Instructions)

    CO

     

    8


     

    CUSIP No. 926613100

     

     

     

    1.

     

    Names of Reporting Persons.

    XYXY Holdings Ltd.

    2.

     

    Check the Appropriate Box if a Member of a Group (See Instructions).

    (a) o (b) o

    3.

     

    SEC Use Only

    4.

     

    Source of Funds (See Instructions)

    N/A

    5.

     

    Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

    o

    6.

     

    Citizenship or Place of Organization

    British Virgin Islands

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With

     

    7.

     

    Sole Voting Power

    0

     

    8.

     

    Shared Voting Power

    0

     

    9.

     

    Sole Dispositive Power

    0

     

    10.

     

    Shared Dispositive Power

    0

    11.

     

    Aggregate Amount Beneficially Owned by Each Reporting Person

    0

    12.

     

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

    o

    13.

     

    Percent of Class Represented by Amount in Row (11)

    0%

    14.

     

    Type of Reporting Person (See Instructions)

    CO

     

    9


     

    CUSIP No. 926613100

     

     

     

    1.

     

    Names of Reporting Persons.

    Xiaomeng Tong

    2.

     

    Check the Appropriate Box if a Member of a Group (See Instructions).

    (a) o (b) o

    3.

     

    SEC Use Only

    4.

     

    Source of Funds (See Instructions)

    N/A

    5.

     

    Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

    o

    6.

     

    Citizenship or Place of Organization

    Hong Kong

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With

     

    7.

     

    Sole Voting Power

    0

     

    8.

     

    Shared Voting Power

    0

     

    9.

     

    Sole Dispositive Power

    0

     

    10.

     

    Shared Dispositive Power

    0

    11.

     

    Aggregate Amount Beneficially Owned by Each Reporting Person

    0

    12.

     

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

    o

    13.

     

    Percent of Class Represented by Amount in Row (11)

    0%

    14.

     

    Type of Reporting Person (See Instructions)

    IN

     

    10


     

    Item 1. Security and Issuer

     

    Item 1 of the Schedule 13D is hereby amended and restated in its entirety as follows:

     

    This Amendment No. 3 to Schedule 13D (the “Amendment No.3”) amends and supplements the statement on Schedule 13D that was originally filed on October 17, 2019, as amended and supplemented by the Amendment No. 1 filed jointly on June 8, 2020 and the Amendment No.2 filed jointly on February 10, 2021 (as so amended and supplemented, the “Schedule 13D”) by Boundless Meadow Limited (“Boundless Meadow”), Boyu Capital Fund III, L.P. (“BCF III”), Boyu Capital General Partner III, L.P. (“BCGP III LP”), Boyu Capital General Partner III, Ltd. (“BCGP III Ltd”), Boyu Capital Opportunities Master Fund (“BCOMF”), Boyu Capital Investment Management Ltd. (“BCIM”), Boyu Capital Group Holdings Ltd. (“BCGH”), XYXY Holdings Ltd. (“XYXY Holdings”) and Xiaomeng Tong (“Mr. Tong”, together with Boundless Meadow, BCF III, BCGP III LP, BCGP III Ltd, BCOMF, BCIM, BCGH and XYXY Holdings, the “Reporting Persons”). The class of equity securities to which this statement relates is the common stock, $0.001 par value per share (the “Common Stock”), of Viela Bio, Inc., a Delaware corporation (the “Company”). The principal executive offices of the Company are located at One MedImmune Way, First Floor, Area Two, Gaithersburg, Maryland 20878. The Common Stock are listed on The Nasdaq Global Select Market under the symbol “VIE.”

     

    Capitalized terms used and not defined in this Amendment No.3 shall have the meanings set forth in the Schedule 13D. Except as otherwise provided herein, all Items of the Schedule 13D remain unchanged.

     

    Item 4. Purpose of Transaction.

     

    Item 4 of the Schedule 13D is hereby amended by adding the following text after the last paragraph thereof:

     

    Each of Boundless Meadow and BCOMF has tendered into the Offer all of shares of Common Stock beneficially owned by it pursuant to the Tender and Support Agreement. As of one minute following 11:59 p.m. Eastern time on March 12, 2021, the Offer expired as scheduled and was not extended. Purchaser was advised by American Stock Transfer & Trust Company, LLC, the depositary for the Offer (the “Depositary”), that, as of the time of the expiration of the Offer, a total of 51,668,285 shares of Common Stock (the “Company Shares”) (not including any Company Shares tendered pursuant to guaranteed delivery procedures that have not yet been “received,” as such term is defined in Section 251(h) of the General Corporation Law of the State of Delaware, as amended (the “DGCL”), by the Depositary pursuant to such procedures) were validly tendered pursuant to the Offer and not validly withdrawn, representing approximately 94% of the Company Shares outstanding as of the time of the expiration of the Offer. In addition, the Depositary advised that notices of guaranteed delivery had been delivered with respect to 991,504 additional Company Shares, representing approximately 1.80% of the outstanding Company Shares as of the time of the expiration of the Offer.

     

    The number of Company Shares tendered pursuant to the Offer satisfied the minimum tender condition set forth in the Merger Agreement. All conditions to the Offer having been satisfied, Purchaser irrevocably accepted for payment and will promptly pay for all Company Shares validly tendered pursuant to the Offer and not validly withdrawn prior to the time of the expiration of the Offer in accordance with the terms of the Offer.

     

    Following the consummation of the Offer, Parent and Purchaser completed the acquisition of the Company on March 15, 2021 through the merger of Purchaser into and with the Company (the “Merger”) without a vote of the shareholders of the Company in accordance with Section 251(h) of the DGCL. At the effective time of the Merger (the “Effective Time”), each Company Share then outstanding (except for Company Shares held by the Company, Parent or Purchaser, which were cancelled and retired and cease to exist, with no consideration delivered in exchange therefor) was cancelled and (other than Company Shares that were held by any shareholders who properly demanded appraisal in connection with the Merger) was converted into the right to receive a price of $53.00 per share in cash, without interest, less any required withholding taxes.

     

    Following the consummation of the Merger, the Company Shares will be delisted and will cease to trade on Nasdaq.

     

    Item 5. Interest in Securities of the Issuer.

     

    Item 5 of the Schedule 13D is hereby amended and supplemented as follows:

     

    (a)-(b) See Items 11 and 13 of the cover pages to this Amendment No.3 for the aggregate number and percentage of Common Stock that are beneficially owned by each Reporting Person as of the date hereof. See Items 7 through 10 of the cover pages to this Amendment No.3 for the number of Common Stock that are beneficially owned by each Reporting Person as of the date hereof as to whether there is sole or shared power to vote or direct the vote, and sole or shared power to dispose or direct the disposition.

     

    11


     

    (c) Except as disclosed elsewhere in this Amendment No.3, none of the Reporting Persons, and to the knowledge of the Reporting Persons, none of the general partners, directors or executive officers named on Schedule I hereto, has effected any transactions in the Common Stock in the last 60 days.

     

    (d) To the knowledge of the Reporting Persons, no one other than the Reporting Persons, or the partners, members, affiliates or shareholders of the Reporting Persons has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of Common Stock covered by this Amendment No.3.

     

    (e) With effect from closing of the transactions contemplated under the Merger Agreement on March 15, 2021, each of the Reporting Persons ceased to be the beneficial owner of more than five percent of the class of securities of the Company. Accordingly, this is an exit filing and the Reporting Persons’ final amendment to Schedule 13D.

     

    12


     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: March 17, 2021

     

     

    Boundless Meadow Limited

     

     

     

     

     

    By:

    /s/ Leong Chu Yong

     

     

    Name:

    Leong Chu Yong

     

     

    Title:

    Director

     

     

     

     

     

    Boyu Capital Fund III, L.P.
    By: Boyu Capital General Partner III, L.P.
    By: Boyu Capital General Partner III, Ltd.

     

     

     

     

     

    By

    /s/ Leong Chu Yong

     

     

    Name:

    Leong Chu Yong

     

     

    Title:

    Director

     

     

     

     

     

    Boyu Capital General Partner III, L.P.
    By: Boyu Capital General Partner III, Ltd.

     

     

     

     

     

    By

    /s/ Leong Chu Yong

     

     

    Name:

    Leong Chu Yong

     

     

    Title:

    Director

     

     

     

     

     

    Boyu Capital General Partner III, Ltd.

     

     

     

     

     

    By:

    /s/ Leong Chu Yong

     

     

    Name:

    Leong Chu Yong

     

     

    Title:

    Director

     

    13


     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: March 17, 2021

     

     

    Boyu Capital Opportunities Master Fund

     

     

     

     

     

    By:

    /s/ Vincent Fok

     

     

    Name:

    Vincent Fok

     

     

    Title:

    Director

     

    14


     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: March 17, 2021

     

     

     

    Boyu Capital Investment Management Ltd.

     

     

     

     

     

    By:

    /s/ Qi Zhou

     

     

    Name:

    Qi Zhou

     

     

    Title:

    Director

     

     

     

     

     

    Boyu Capital Group Holdings Ltd.

     

     

     

     

     

    By:

    /s/ Leong Chu Yong

     

     

    Name:

    Leong Chu Yong

     

     

    Title:

    Director

     

     

     

     

     

    XYXY Holdings Ltd.

     

     

     

     

     

    By:

    /s/ Leong Chu Yong

     

     

    Name:

    Leong Chu Yong

     

     

    Title:

    Director

     

    15


     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: March 17, 2021

     

     

    Xiaomeng Tong

     

     

     

    By:

    /s/ Xiaomeng Tong

     

    16


    Get the next $VIE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VIE

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $VIE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Viela Bio Reports Fourth Quarter and Full Year 2020 Operating and Financial Results

      GAITHERSBURG, Md., March 01, 2021 (GLOBE NEWSWIRE) -- Viela Bio (Nasdaq:VIE), a biotechnology company dedicated to the discovery, development and commercialization of novel treatments for patients suffering from autoimmune and severe inflammatory diseases, today reported financial results and provided program and business highlights for the fourth quarter and full year ended December 31, 2020. “2020 was a year of great progress for Viela, despite the many external challenges resulting from the COVID-19 global pandemic,” said Bing Yao, Ph.D., Chief Executive Officer at Viela Bio. “Most significantly, we received FDA approval for UPLIZNA® to treat adult patients with AQP4+ NMOSD and achieve

      3/1/21 4:01:00 PM ET
      $VIE
      Major Pharmaceuticals
      Health Care
    • Viela Bio Announces Additional Positive Results with UPLIZNA® (inebilizumab-cdon) in Patients with Neuromyelitis Optica Spectrum Disorder at the ACTRIMS 2021 Forum

      -No new safety signals were identified with prolonged inebilizumab treatment and inebilizumab-mediated B-cell depletion- -UPLIZNA was shown to be safe and effective in patients with previous exposure to off-label therapy- GAITHERSBURG, Md., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Viela Bio (Nasdaq:VIE), a biotechnology company dedicated to the discovery, development and commercialization of novel treatments for patients suffering from autoimmune and severe inflammatory diseases, today reported updated safety, efficacy and long-term use results of UPLIZNA® (inebilizumab-cdon), including interim data from the open-label extension period (OLP) of the pivotal N-MOmentum trial in patients with neur

      2/25/21 8:30:00 AM ET
      $VIE
      Major Pharmaceuticals
      Health Care
    • Ambrx Appoints Audit Executive Chris Nolet to Board of Directors

      SAN DIEGO--(BUSINESS WIRE)--​Ambrx, a clinical stage biopharmaceutical company using an expanded genetic code to create Engineered Precision Biologics, today announced the appointment of Chris Nolet to the company’s Board of Directors. Mr. Nolet brings extensive experience as a long-time audit partner and business advisor in the life sciences industry, and has assumed the role of Chair of Ambrx’s Audit Committee. “We are delighted that Chris will be joining our Board of Directors given his deep expertise, knowledge base and industry network,” said Feng Tian, Ph.D., President and CEO of Ambrx. “His experience in helping transition clinical stage companies into commercially integra

      2/23/21 4:05:00 PM ET
      $VIE
      $PTE
      $RVNC
      Major Pharmaceuticals
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
      Biotechnology: Pharmaceutical Preparations

    $VIE
    Leadership Updates

    Live Leadership Updates

    See more
    • Ambrx Appoints Audit Executive Chris Nolet to Board of Directors

      SAN DIEGO--(BUSINESS WIRE)--​Ambrx, a clinical stage biopharmaceutical company using an expanded genetic code to create Engineered Precision Biologics, today announced the appointment of Chris Nolet to the company’s Board of Directors. Mr. Nolet brings extensive experience as a long-time audit partner and business advisor in the life sciences industry, and has assumed the role of Chair of Ambrx’s Audit Committee. “We are delighted that Chris will be joining our Board of Directors given his deep expertise, knowledge base and industry network,” said Feng Tian, Ph.D., President and CEO of Ambrx. “His experience in helping transition clinical stage companies into commercially integra

      2/23/21 4:05:00 PM ET
      $VIE
      $PTE
      $RVNC
      Major Pharmaceuticals
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
      Biotechnology: Pharmaceutical Preparations

    $VIE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Yanling Cao disposed to the issuer $441,084,709 worth of Common Stock (8,322,353 units at $53.00)

      4 - Viela Bio, Inc. (0001734517) (Issuer)

      3/16/21 5:13:43 PM ET
      $VIE
      Major Pharmaceuticals
      Health Care
    • SEC Form 4 filed by Tyrell Rivers

      4 - Viela Bio, Inc. (0001734517) (Issuer)

      3/16/21 8:53:24 AM ET
      $VIE
      Major Pharmaceuticals
      Health Care
    • SEC Form 4 filed by Plc Astrazeneca

      4 - Viela Bio, Inc. (0001734517) (Issuer)

      3/16/21 8:52:55 AM ET
      $VIE
      Major Pharmaceuticals
      Health Care

    $VIE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Viela Bio downgraded by Guggenheim

      Guggenheim downgraded Viela Bio from Buy to Neutral

      2/8/21 11:51:17 AM ET
      $VIE
      Major Pharmaceuticals
      Health Care
    • Viela Bio downgraded by Wedbush

      Wedbush downgraded Viela Bio from Outperform to Neutral

      2/8/21 7:28:49 AM ET
      $VIE
      Major Pharmaceuticals
      Health Care
    • Viela Bio downgraded by Wedbush with a new price target

      Wedbush downgraded Viela Bio from Outperform to Neutral and set a new price target of $43.00

      2/8/21 7:26:43 AM ET
      $VIE
      Major Pharmaceuticals
      Health Care

    $VIE
    SEC Filings

    See more
    • SEC Form 15-12B filed by Viela Bio, Inc.

      15-12B - Viela Bio, Inc. (0001734517) (Filer)

      3/25/21 4:01:54 PM ET
      $VIE
      Major Pharmaceuticals
      Health Care
    • SEC Form S-8 POS filed by Viela Bio, Inc.

      S-8 POS - Viela Bio, Inc. (0001734517) (Filer)

      3/15/21 9:15:53 AM ET
      $VIE
      Major Pharmaceuticals
      Health Care
    • SEC Form S-8 POS filed by Viela Bio, Inc.

      S-8 POS - Viela Bio, Inc. (0001734517) (Filer)

      3/15/21 9:12:58 AM ET
      $VIE
      Major Pharmaceuticals
      Health Care

    $VIE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Viela Bio, Inc.

      SC 13D/A - Viela Bio, Inc. (0001734517) (Subject)

      3/17/21 7:40:24 AM ET
      $VIE
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - Viela Bio, Inc. (0001734517) (Subject)

      3/10/21 9:46:40 AM ET
      $VIE
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - Viela Bio, Inc. (0001734517) (Subject)

      2/16/21 4:22:37 PM ET
      $VIE
      Major Pharmaceuticals
      Health Care